Investigational Drug Information for LY3200882
✉ Email this page to a colleague
What is the development status for investigational drug LY3200882?
LY3200882 is an investigational drug.
There have been 4 clinical trials for LY3200882.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 5th 2019.
The most common disease conditions in clinical trials are Neoplasms, Colorectal Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Eli Lilly and Company, Catalan Institute of Health, and European Organisation for Research and Treatment of Cancer - EORTC.
There are three US patents protecting this investigational drug.
Summary for LY3200882
| US Patents | 3 |
| International Patents | 0 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2019-12-05) |
| Vendors | 46 |
Recent Clinical Trials for LY3200882
| Title | Sponsor | Phase |
|---|---|---|
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) | Agendia | Phase 1/Phase 2 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) | Azienda Ospedaliera Niguarda Cà Granda | Phase 1/Phase 2 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) | Catalan Institute of Health | Phase 1/Phase 2 |
Clinical Trial Summary for LY3200882
Top disease conditions for LY3200882
Top clinical trial sponsors for LY3200882
US Patents for LY3200882
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY3200882 | ⤷ Start Trial | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | Inventisbio Co Ltd | ⤷ Start Trial |
| LY3200882 | ⤷ Start Trial | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | Inventisbio Co Ltd | ⤷ Start Trial |
| LY3200882 | ⤷ Start Trial | Aminopyridyloxypyrazole compounds | Eli Lilly and Co | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
